Dermata Piotroski F Score

DRMA -  USA Stock  

USD 1.68  0.17  11.26%

This module uses fundamental data of Dermata Therapeutics to approximate its Piotroski F score. Dermata Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Dermata Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Dermata Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to Dermata Therapeutics Altman Z Score, Dermata Therapeutics Correlation, Dermata Therapeutics Valuation, as well as analyze Dermata Therapeutics Alpha and Beta and Dermata Therapeutics Hype Analysis.

Dermata Piotroski F Score 

 
Refresh
The current year Issuance Repayment of Debt Securities is expected to grow to about 2.9 M, whereas Total Debt is forecasted to decline to about 3.5 M.
At this time, it appears that Dermata Therapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
3.0
Piotroski F Score - Frail
1
Current Return On Assets
Negative
2
Change in Return on Assets
Decreased
3
Cash Flow Return on Assets
Negative
4
Current Quality of Earnings (accrual)
Decreasing
5
Asset Turnover Growth
N/A
6
Current Ratio Change
Increase
7
Long Term Debt Over Assets Change
Lower Leverage
8
Change In Outstending Shares
Decrease
9
Change in Gross Margin
N/A

Dermata Therapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Dermata Therapeutics is to make sure Dermata is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Dermata Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Dermata Therapeutics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares1.7 M1.7 M
Slightly Down
Decreasing
Slightly volatile
Weighted Average Shares Diluted1.7 M1.7 M
Slightly Down
Decreasing
Slightly volatile
Total Assets849.2 K544.9 K
Way Up
Decreasing
Slightly volatile
Total LiabilitiesM4.4 M
Significantly Down
Increasing
Slightly volatile
Current Assets849.1 K544.9 K
Way Up
Decreasing
Slightly volatile
Current Liabilities3.9 M4.4 M
Fairly Down
Increasing
Slightly volatile
Total Debt3.5 M4.1 M
Fairly Down
Increasing
Slightly volatile

Dermata Therapeutics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Dermata Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Dermata Therapeutics in a much-optimized way.

About Dermata Therapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value per Share

(1.54)Share
Dermata Therapeutics Book Value per Share is projected to slightly decrease based on the last few years of reporting. The past year's Book Value per Share was at -1.5

About Dermata Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Dermata Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dermata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dermata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company was founded in 2014 and is headquartered in San Diego, California. Dermata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 7 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Dermata Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Focused Opportunities Now

   

Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Pair Trading with Dermata Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dermata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Dermata Therapeutics Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Dermata Therapeutics and Brickell Biotech. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Dermata Therapeutics Altman Z Score, Dermata Therapeutics Correlation, Dermata Therapeutics Valuation, as well as analyze Dermata Therapeutics Alpha and Beta and Dermata Therapeutics Hype Analysis. Note that the Dermata Therapeutics information on this page should be used as a complementary analysis to other Dermata Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Dermata Stock analysis

When running Dermata Therapeutics price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Is Dermata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. If investors know Dermata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dermata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Dermata Therapeutics is measured differently than its book value, which is the value of Dermata that is recorded on the company's balance sheet. Investors also form their own opinion of Dermata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dermata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dermata Therapeutics' market value can be influenced by many factors that don't directly affect Dermata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dermata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Dermata Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.